Literature DB >> 27605113

High-Resolution Snapshots of Proteasome Inhibitors in Action Revise Inhibition Paradigms and Inspire Next-Generation Inhibitor Design.

Kimberly Carmony1, Wooin Lee2, Kyung Bo Kim1.   

Abstract

New high-resolution crystal structures reported by Schrader and colleagues refine our understanding of how peptide epoxyketone anticancer drugs inactivate their target: the human proteasome. These findings provide important clues for the design of next-generation proteasome inhibitor drugs.
© 2016 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  drug design; epoxyketone; oprozomib; proteasome inhibitors; proteasome structures

Mesh：

Substances：

Year:  2016        PMID： 27605113      PMCID： PMC5192039          DOI： 10.1002/cbic.201600488

Source DB:  PubMed          Journal:  Chembiochem        ISSN： 1439-4227            Impact factor:   3.164


  11 in total

1.  The structure of the mammalian 20S proteasome at 2.75 A resolution.

Authors:  Masaki Unno; Tsunehiro Mizushima; Yukio Morimoto; Yoshikazu Tomisugi; Keiji Tanaka; Noritake Yasuoka; Tomitake Tsukihara
Journal:  Structure       Date:  2002-05       Impact factor: 5.006

2.  Elucidation of the α-keto-aldehyde binding mechanism: a lead structure motif for proteasome inhibition.

Authors:  Melissa Ann Gräwert; Nerea Gallastegui; Martin Stein; Boris Schmidt; Peter-Michael Kloetzel; Robert Huber; Michael Groll
Journal:  Angew Chem Int Ed Engl       Date:  2011-01-10       Impact factor: 15.336

3.  Crystal structure of the human 20S proteasome in complex with carfilzomib.

Authors:  Wayne Harshbarger; Chase Miller; Chandler Diedrich; James Sacchettini
Journal:  Structure       Date:  2015-01-15       Impact factor: 5.006

4.  The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design.

Authors:  Jil Schrader; Fabian Henneberg; Ricardo A Mata; Kai Tittmann; Thomas R Schneider; Holger Stark; Gleb Bourenkov; Ashwin Chari
Journal:  Science       Date:  2016-08-05       Impact factor: 47.728

Review 5.  A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma.

Authors:  Elisa Gallerani; Massimo Zucchetti; Dario Brunelli; Elena Marangon; Cristina Noberasco; Dagmar Hess; Angelo Delmonte; Giovanni Martinelli; Steffen Böhm; Christopher Driessen; Filippo De Braud; Silvia Marsoni; Roberta Cereda; Federica Sala; Maurizio D'Incalci; Cristiana Sessa
Journal:  Eur J Cancer       Date:  2012-10-08       Impact factor: 9.162

Review 6.  Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.

Authors:  Jason M Steele
Journal:  J Oncol Pharm Pract       Date:  2013-01-04       Impact factor: 1.809

7.  Structure of 20S proteasome from yeast at 2.4 A resolution.

Authors:  M Groll; L Ditzel; J Löwe; D Stock; M Bochtler; H D Bartunik; R Huber
Journal:  Nature       Date:  1997-04-03       Impact factor: 49.962

8.  A protein catalytic framework with an N-terminal nucleophile is capable of self-activation.

Authors:  J A Brannigan; G Dodson; H J Duggleby; P C Moody; J L Smith; D R Tomchick; A G Murzin
Journal:  Nature       Date:  1995-11-23       Impact factor: 49.962

9.  Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome.

Authors:  Michael Groll; Celia R Berkers; Hidde L Ploegh; Huib Ovaa
Journal:  Structure       Date:  2006-03       Impact factor: 5.006

Review 10.  Spotlight on ixazomib: potential in the treatment of multiple myeloma.

Authors:  Barbara Muz; Rachel Nicole Ghazarian; Monica Ou; Micah John Luderer; Hubert Daniel Kusdono; Abdel Kareem Azab
Journal:  Drug Des Devel Ther       Date:  2016-01-11       Impact factor: 4.162
View more
  5 in total

Review 1.  Next-generation proteasome inhibitors for cancer therapy.

Authors:  Ji Eun Park; Zachary Miller; Yearin Jun; Wooin Lee; Kyung Bo Kim
Journal:  Transl Res       Date:  2018-03-26       Impact factor: 7.012

2.  The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.

Authors:  G R Tundo; D Sbardella; A M Santoro; A Coletta; F Oddone; G Grasso; D Milardi; P M Lacal; S Marini; R Purrello; G Graziani; M Coletta
Journal:  Pharmacol Ther       Date:  2020-05-19       Impact factor: 12.310

3.  A dual inhibitor of the proteasome catalytic subunits LMP2 and Y attenuates disease progression in mouse models of Alzheimer's disease.

Authors:  In Jun Yeo; Min Jae Lee; Ahruem Baek; Zachary Miller; Deepak Bhattarai; Yu Mi Baek; Hyun Jung Jeong; Yun Kyung Kim; Dong-Eun Kim; Jin Tae Hong; Kyung Bo Kim
Journal:  Sci Rep       Date:  2019-12-05       Impact factor: 4.379

4.  Proteasomal adaptations to FDA-approved proteasome inhibitors: a potential mechanism for drug resistance?

Authors:  Kyung Bo Kim
Journal:  Cancer Drug Resist       Date:  2021-05-30

5.  Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.

Authors:  Jun-Hai Tang; Lin Yang; Ju-Xiang Chen; Qing-Rui Li; Li-Rong Zhu; Qing-Fu Xu; Guo-Hao Huang; Zuo-Xin Zhang; Yan Xiang; Lei Du; Zheng Zhou; Sheng-Qing Lv
Journal:  Cancer Commun (Lond)       Date:  2019-12-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.